The Place of Cannabinoids in the Treatment of Gynecological Pain

Cannabis sativa (L), a plant with an extensive history of medicinal usage across numerous cultures, has received increased attention over recent years for its therapeutic potential for gynecological disorders such as endometriosis, chronic pelvic pain, and primary dysmenorrhea, due at least in part to shortcomings with current management options. Despite this grow - ing interest, cannabis inhabits an unusual position in the modern medical pharmacopoeia, being a legal medicine, legal recreational drug, and an illicit drug, depending on jurisdiction. To date, the majority of studies investigating cannabis use have found that most people are using illicit cannabis, with numerous obstacles to medical cannabis adoption having been identified, including outdated drug-driving laws, workplace drug testing policies, the cost of quality-assured medical can- nabis products, a lack of cannabis education for healthcare professionals, and significant and persistent stigma. Although currently lacking robust clinical trial data, a growing evidence base of retrospective data, cohort studies, and surveys does support potential use in gynecological pain conditions, with most evidence focusing on endometriosis. Cannabis consumers report substantial reductions in pelvic pain, as well as common comorbid symptoms such as gastrointestinal disturbances, mood disorders such as anxiety and depression, and poor sleep. Substitution effects were reported, with >50% reduction or cessation in opioid and/or non-opioid analgesics being the most common. However, a substantial minority report not disclos- ing cannabis consumption to their health professional. Therefore, while such deprescribing trends are potentially beneficial, the importance of medical supervision during this process is paramount given the possibility for withdrawal symptoms. Plain Language Summary Cannabis, whether purchased illicitly, or obtained through legal means, is commonly used by those with chronic pelvic pain, especially people with endometriosis. People report several benefits from using cannabis, including being able to reduce their normal medications including opioid based painkillers, but often don’t tell their health professional about this. This could lead to issues with withdrawal symptoms, so clinicians should be aware of the high prevalence of use of cannabis in this population. * Justin Sinclair [email protected] * Mike Armour [email protected] 1 NICM Health Research Institute, Western Sydney University, Sydney, NSW, Australia 2 Division of Obstetrics and Gynaecology, School of Clinical Medicine, Medicine and Health, UNSW, Sydney, NSW, Australia 3 Gynaecological Research and Clinical Research (GRACE) Unit, Royal Hospital for Women, UNSW, Sydney, NSW, Australia 4 Translational Health Research Institute, Western Sydney University, Sydney, NSW, Australia 5 Medical Research Institute of New Zealand (MRINZ), Wellington, New Zealand Key Points Robust clinical trial data is currently lacking for gyneco- logical pain conditions. Despite this, cannabis is being used to treat gynecologi- cal pain, especially in those with endometriosis or other forms of chronic pelvic pain, with reductions in symp- toms such as pelvic pain commonly reported. Cannabis consumption for gynecological pain should be undertaken under medical supervision, especially when reducing pharmaceutical interventions like opioids. 1572 J. Sinclair et al. 1 Introduction Current global estimates suggest 39.6% of women and those assigned female at birth* (hereafter denoted as women)—or approximately 1.53 billion people, live with gynecological disease [1], with pain often a key symptom. The most com- mon causes of gynecological pain are primary or secondary dysmenorrhea, with over 70% of women reporting dysmen- orrhea (period pain) at some stage of their life [2 ]. Primary dysmenorrhea is defined as menstrual pain in the absence of underlying structural changes [3]. Primary dysmenorrhea’s characteristic symptom is crampy, colicky spasms of pain in the suprapubic area, occurring within 8–72 h of menstrua- tion and peaking within the first few days as menstrual flow increases [3, 4]. In addition to painful cramps, many women with primary dysmenorrhea experience other menstrual- related symptoms, including back and thigh pain, headaches, diarrhea, nausea, and vomiting [4]. The largest contributing physiological factor in primary dysmenorrhea is increased amounts of prostaglandins present in the menstrual fluid [5]. If there is no pregnancy after ovulation, progesterone levels decline in the late luteal phase of the cycle. Reduction in progesterone levels destabilizes cell membranes in endo- metrial tissue and causes the hydrolyzation of cell mem- brane phospholipids (mainly omega-6) to form arachadonic acid. Arachadonic acid is converted via the cyclooxygenase pathway to prostaglandins PGE2 and PGF2a [5 , 6]. These excess prostaglandins are released when the endometrial lin- ing breaks down during menses. Prostaglandins, especially PGF2a, stimulate myometrial contractions, reducing uterine blood flow and causing uterine hypoxia. This is responsible for the painful cramping that characterizes primary dysmen- orrhea [5 , 7]. Secondary dysmenorrhea is menstrual pain associated with structural changes in the pelvis or an identifi- able cause such as endometriosis [4]. In Australia and other high-income countries, persistent dysmenorrhea is reported in over 90% of women and girls under age 25 years [8 , 9]. Dysmenorrhea may lead to absenteeism at work [10], and affect attendance and academic performance both at school and in tertiary education [2 ], with many people reporting inadequate symptom management [11–13]. Chronic pelvic pain (CPP), defined as pain in the pel- vis for > 6 months’ duration that is severe enough to cause functional disability or require medical intervention [14] is a common type of gynecological pain [15– 17]. CPP may be cyclic, non-cyclic or both [ 18] and commonly includes dysmenorrhea (period pain), non-cyclical pelvic pain, dys- pareunia (painful intercourse), dysuria (pain on urination), and dyschezia (pain on defecation) [19]. CPP affects one in four women (26%) [18, 20], accounting for 40% of laparos- copies, 10% of specialist gynecology consultations, and 12% of hysterectomies in the USA annually [18]. CPP includes conditions such as endometriosis, adenomyosis, vulvodynia, interstitial cystitis, and bladder pain syndrome [19, 21, 22], with endometriosis the single most prevalent disease in this group [23]. Symptom management is frequently challenging due to involvement of neuropathic, nociplastic, and nocicep- tive pain pathways [21]. Current management strategies for gynecological pain depend on its underlying cause. Primary dysmenorrhea is commonly managed by non-steroidal anti-inflammatory drugs (NSAIDs) and/or the oral contraceptive pill as first- line treatment(s) [24], however a significant number of women report less than optimal symptom management, with 25% of those using ibuprofen and 35% of those using paracetamol reporting no reduction in dysmenorrhea sever- ity [12]. This may explain why women are open to using other treatments such as cannabis to manage their primary dysmenorrhea symptoms [13]. Current treatments for endo- metriosis and chronic pelvic pain are generally considered suboptimal by those with the disease [15, 25], with only 25% of those with endometriosis being satisfied with their symptom management [25]. There are concerns about lack of effectiveness and problematic side effects of many medi- cations for pelvic pain, leading to discontinuation rates of 25–50% [26]. Opioid analgesics are not recommended for chronic pelvic pain due to both a lack of efficacy and safety concerns with respect to ongoing use [27]. However, despite this they continue to be prescribed; women with endometrio- sis have a four times greater risk of chronic opioid use com- pared with women with no endometriosis [28]. For those with endometriosis, surgery is considered the gold standard but often has significant costs, long waiting times [29], and substantial recurrence rates, even with expert endometriosis surgeons [30]. Given the prevalence of gynecological pain, its delete- rious effect on quality of life, and the current difficulties in managing this pain, finding effective, safe interventions with low addictive/dependence potential is identified as an international priority [31– 33]. 2 Historical Use of Cannabis Cannabis sativa is one of the oldest cultivated plants utilized by humans, being used as a food, textile and as a medicine for millennia [34–36]. The Ebers Papyrus (1550 BCE) from ancient Egypt describes the use of cannabis to aid child - birth [37]. In ancient China, the use of cannabis for female reproductive symptoms was reported in the Pen-Tsao Ching, based on the oral traditions passed down from the Emperor Shen-Nung, who lived circa 2700 BCE [36, 38]. The age- old Indian Atharva Veda of 1000 BCE described cannabis as a sacred plant, used as an analgesic, anesthetic, anti- inflammatory, anti-spasmodic, and hypnotic medicine [36]. 1573 Cannabis for Gynecological Conditions More recently, the Chinese Bencao Gang Mu compiled in 1596 recommended cannabis flowers for menstrual disorders [37], the Persians utilized it for calming uterine pains [37], African cultures utilized it to facilitate childbirth, and South American cultures reported its utility for menstrual cramps in the 16th century [36]. Cannabis was introduced to Western medicine in 1842 by the Irish physician O’Shaughnessy [37]. Soon after, it was acknowledged in the Dispensatory of the United States, and tinctures of cannabis were prescribed to manage uter - ine hemorrhage [39], assistance in childbirth [40], neuralgic dysmenorrhea [41], hyperemesis gravidarum, dysmenorrhea, and heavy menstrual bleeding—the latter being published in the British Medical Journal [ 37, 42]. In the 19th cen- tury, cannabis was also prescribed as an anodyne in chronic metritis, endometritis, and chronic cystitis [37]. Importantly, cannabis was found to have advantages over opiates for pain [43], and could also be useful for opiate withdrawal [44–46]. Notwithstanding its widespread popularity, can- nabis started falling out of favor as a medical treatment in the early 20th century, due mainly to a lack of quality assurance and standardization from imported material [47]—factors that were being addressed by the newly birthed pharmaceu- tical industry and its single active drug model. However, with the implementation of the Marihuana Tax Act in 1937 [48], which effectively criminalized the possession and use of cannabis as a medicine in the US, widespread medical use largely ceased. Cannabis was subsequently removed from the United States Pharmacopoeia in 1942 and was added to the United Nation’s Single Convention on Narcotic Drugs in 1961. Cannabis was prohibited through the US Controlled Substances Act of 1970 where it was classified as a Schedule 1 controlled substance—defined as having no accepted medicinal use, high abuse potential, and con- cerns for dependence [48]. Whilst history suggests that the drivers for this prohibitionist position were more idealistic than evidence-based [49, 50], the fact remains that Cannabis sativa remains a largely prohibited substance globally, with changes to legislation only relatively recently allowing for medicinal use in a growing number of nations. Despite decades of prohibition and Schedule 1 relegation, research into the therapeutic potential of cannabis continued largely unabated, with two of the main active constituents of cannabis, the terpeno-phenolic cannabinoids cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) discovered in 1940 and 1964, respectively [51, 52]. Cannabidiol, a non- intoxicating cannabinoid, has a wide range of pharmaco - logical activities, including neuroprotective, anti-convulsant, anxiolytic, analgesic, anti-depressant, antioxidant, and anti- inflammatory properties [53– 58]. THC also has a broad array of pharmacological actions, including analgesic, anti- emetic, anti-inflammatory, muscle relaxant, and sedative properties [59–62]—all of which can be of potential benefit to gynecological pain conditions, but must be balanced with its intoxicating effects. To date, there are over 144 different cannabinoids identified across the Cannabis genus [63], with research ongoing into their pharmacological activities and potential benefit in human health. Additional research has also identified an entire neuromodulatory system within the body—the endocannabinoid system (ECS)—with receptors identified in most organ systems, including the female repro- ductive system, resulting in various changes to physiological processes [64]. 3 Mechanisms of Action The ECS consists of G-protein coupled receptors (i.e., Can- nabinoid 1 and 2 receptors), endogenous ligands (i.e., the endocannabinoids), and ligand metabolic enzymes [65] responsible for the synthesis and degradation of endocan- nabinoids. More broadly, the ECS is involved in the mod- ulation of a host of physiological responses, inclusive of inflammation, nociception, appetite regulation, respiration, and metabolism [66], with more recent research highlighting ECS involvement across many aspects of the female repro- ductive system. The ECS engages in a complex interplay with the hypothalamic pituitary ovarian (HPO) axis to exert control over certain female reproductive processes [67], including pain modulation, oocyte maturation, ovarian endo- crine secretion, folliculogenesis, uterine decidualization and placentation, implantation, and embryo transport [67– 69]. Research into the role of ECS in gynecological conditions has highlighted that elevated systemic levels of endocan- nabinoids (i.e., anandamide and 2-arachidonoyl glycerol [2-AG]), along with decreased local cannabinoid 1 receptor (CB1) expression are present in people with endometriosis [70], and that the ECS may be a promising target to address endometriosis-related pain [71–73]. Furthermore, alterations in ECS homeostasis may lead to dysfunctional modulation of cellular processes involved in reproductive pathologies, namely pre-eclampsia, miscarriage, and ectopic pregnancy [74]. Research also posits that ECS dysfunction is involved in the pathogenesis of dysmenorrhea in adenomyosis [75]. Proposed mechanisms by which both endocannabinoids and cannabinoids exert analgesic effect across gynecologi- cal pain and associated disorders are numerous and inter- related. Neural and non-neural cells produce arachidonic acid derivatives known as endocannabinoids in response to tissue injury [76]. These endocannabinoids, mainly anan- damide and 2-AG, modulate neural pain signal conduction by mitigating sensitization and inflammation via activation of cannabinoid receptors, which are also targets for phyto- cannabinoids such as THC [77, 78]. Cannabinoid 1 (CB1) receptors are predominantly expressed throughout the cen- tral nervous system where they modulate neurotransmitter 1574 J. Sinclair et al. release; however, they are also present in the pain-modu- lating areas such as the dorsal root ganglion [ 78], periaq - ueductal grey, and rostral ventral medulla [ 79, 80]. Addi - tionally, CB1-mediated analgesia is not solely via nervous system modulation, but also potentiates anti-inflammatory effects on mast cells [81]. Cannabinoid 2 (CB2) receptors are widely expressed in high concentrations throughout the periphery and immune cells [80], but are also found in lower amounts in the brain and spinal cord [78]. CB2 receptors increase in response to peripheral nerve damage, interfere with inflammatory hyperalgesia, and modulate neuroim- mune activity [78, 82]. Furthermore, CB2 activation inhibits proinflammatory signaling released near nociceptive nerves and can propagate downstream release of opioids [81, 83], and has demonstrated antinociceptive activity in inflamma- tory hyperalgesia and neuropathic pain [84, 85]. Focusing on endometriosis as an exemplar, there are sev- eral drivers for the pain experience, including nociceptive, inflammatory, and neuropathic pain mechanisms which are interconnected and complex to manage [ 73]. Additionally, the psychological impact of the pain experience in people with endometriosis can cause anxiety and pain catastrophiz- ing, with the related sequalae of impacting self-esteem and relationships, worsening the pain experience further [ 73]. Phytocannabinoids from Cannabis spp not only interact with CB1 and CB2 receptors to exert analgesic activity, but also modulate transient receptor potential vanilloid (TRPV) channels which are involved in neuropathic pain signals [81, 86]. Modulation of serotonin receptors (5HT1A) by phytocannabinoids such as cannabidiol can assist in pain through exerting anxiolytic and antidepressant activity, and other antinociceptive effects of cannabinoids have been pro- posed specific to endometriosis, including antiangiogenic, immunomodulating, and antiproliferative activities [81, 87, 88].Whilst more research is needed to fully elucidate the efficacy and safety of cannabis and cannabinoid-based medicinal products in endometriosis and other gynecologi- cal conditions, recent changes in regulatory scheduling of cannabis has opened up this field of research to the broader international scientific community. 4 Access to Medicinal Cannabis With the enactment of the Compassionate Use Act (Propo- sition 215) in 1996, California became the first US state to permit legal access to cannabis for medical reasons under physician supervision [48]. This started a ripple effect throughout the USA, with 37 states allowing legal- ized medicinal cannabis, including seven states allowing access to CBD-containing products only. In contrast, Canada adopted the Marijuana Medical Access Regulations in 2001 that was replaced by the Marijuana for Medical Purposes Regulations in 2014 with no restrictions on the clinical indi- cations for which cannabis could be prescribed [89]. More than 50 countries have followed suit, adopting assorted medicinal cannabis regulatory models [90], including Israel, the United Kingdom, Australia, and New Zealand. Different nations have varying degrees of regulatory oversight and product quality assurance standards. Changes to laws and regulations have also allowed the scientific community to research cannabis more rigorously and allowed people with gynecological pain to access cannabis legally for medicinal purposes. 5 Evidence for Gynecological Pain Conditions Currently there are few properly designed and controlled randomized clinical trials investigating the efficacy of can- nabis for gynecological symptoms, which limits clear guid- ance around clinical recommendations. Until such studies are undertaken, there is a reliance on evidence that is lower on the evidence pyramid, supported by a growing body of retrospective data, cohort studies, and surveys, reporting the positive effects of cannabis from patients with gyneco- logical symptoms [91]. Given poor symptom management [15], long waiting times for endometriosis surgery in some jurisdictions [29], and side effects of many medications for pelvic pain [26], it is perhaps unsurprising that people with CPP are using cannabis as a substitute for, or in addition to, more orthodox treatments. A cross-sectional survey of 240 CPP patients recruited in an outpatient gynecology office reported that one-quarter of patients with CPP used can - nabis regularly as an adjunct to prescribed medicines, with 96% reporting improvements in their symptoms, including 84% reporting improved muscle pain, 72% a reduction in irritability, depression, and anxiety, and 68% an improve- ment in sleep [92]. Similarly, a cross-sectional survey of 484 endometriosis patients in Australia on self-management of endometriosis reported illicit cannabis was the most effec- tive self-management strategy [93]. In this survey, one in ten respondents reported utilizing illicit cannabis for thera- peutic purposes to manage their endometriosis symptoms, with self-reported pain reduction rated at 7.6/10. In addi- tion, over half (56%) of the cohort reported a 50% or more reduction in pharmaceutical medications typically used for endometriosis management [ 93, 94]. From a retrospective, electronic record-based cohort study of 252 patients with self-reported endometriosis, cannabis use for decreasing pelvic pain was described, with inhaled delivery being the most common mode of administration [95]. This prefer - ence for inhalation may be due to the rapid speed of onset of pharmacological effects for inhaled cannabis compared with oral forms [ 96], which could provide better control 1575 Cannabis for Gynecological Conditions for the sudden breakthrough pain that commonly occurs in endometriosis (so called ‘endo flares’). This study also sug- gested improvements in comorbid symptoms such as mood and gastrointestinal symptoms, common in those with endo- metriosis [19], and had greater improvement for oral dosage forms compared with inhaled [95], suggesting that tailoring the mode of administration to target specific symptoms is an important clinical consideration. During the COVID-19 pandemic, an international cross-sectional survey found that 51% of 1634 respondents with endometriosis used cannabis in the 3 months prior [97]. Respondents with legal access were more likely to consume cannabis than those without and were also more likely to disclose their usage to health- care professionals. In many of these studies, a deprescribing or ‘substitution effect’ is reported where uptake in cannabis usage results in a reduction in one or more pharmaceuti- cals [94]. From a cross-sectional study of 213 participants in New Zealand, illicit cannabis use for managing pain and to improve sleep was reported in 95% of respondents, with over 80% (n  = 176/213) indicating that cannabis had reduced their normal pharmaceutical medication usage [98]. Almost two-thirds (n = 128/213) of respondents completely stopped a medication, most commonly analgesics (66%, n = 85/128), with opioids (40%, n = 51/128) being the most common analgesic stopped, followed by NSAIDs at 17% (n = 21/128), antidepressants (16%, n = 20/128), and ben- zodiazepines (15%, n = 9/128) [98]. In a separate study from Australia and New Zealand, 237 people with endometriosis reported substantial substitution effects utilizing predomi- nantly illicit cannabis [99], with a 50% or more reduction in usage being reported for those who currently or previously used opioid analgesia (66%, n = 121/183), non-opioid anal- gesia (63%, n  = 147/233), neuroleptics (61%, n = 37/60), and anxiolytic medications (47.9%, n = 46/96). 6 Risks of Cannabis Usage Cannabis use for gynecological pain, whether legal or illicit, is not without side effects or risks [100]. Factors such as early age of initiation associated with mental ill health in vulnerable populations, dependence, and abuse potential (i.e., particularly THC-dominant cannabis) are important clinical considerations for clinicians to discuss with their patients before prescribing or recommending medicinal can- nabis [96, 100]. The most common side effects reported by cannabis consumers in general include dry mouth, anxiety, nausea, dizziness, drowsiness/fatigue, and cognitive effects [96]. These are similar to those reported by people using cannabis for gynecological pain; 84% of those using can - nabis for pelvic pain reported side effects, most commonly dry mouth, sleepiness, and feeling ‘high’ [92]. In those with endometriosis, just under a third (28%) of cannabis users reported side effects; 75% reported feelings of euphoria, 72% increased appetite, 67% dry mouth, and 35% feelings of mild anxiety or paranoia with medically diagnosed can- nabis; hyperemesis syndrome was reported by only two respondents (<1%) [97]. However, cessation due to these side effects is relatively low, with just under 23% of those who reported cessation of cannabis indicated it was due to side effects [97]. Deprescribing associated with cannabis substitution is promising. However, research suggests that people are not informing their medical doctor of their use of illicit cannabis for therapeutic purposes, citing concerns over legal reper - cussions (combined 31.3%), societal judgment (29.2%), the doctor’s reaction (29.2%), or the doctor’s presumed unwill- ingness to prescribe (10.4%). This is concerning as many of the medications that are being reduced or discontinued, such as opioids and benzodiazepines, have potential for sig- nificant withdrawal [101, 102] if not tapered off correctly under medical supervision. Therefore, doctors who work with patients with endometriosis or other forms of chronic pelvic pain should be aware of the likelihood of potential cannabis usage, and try to encourage disclosure of usage, or at minimum, closely monitor usage of these medications over time. 7 Barriers to Usage Whilst the distinct lack of randomized clinical trial data may be a significant barrier to cannabis adoption for gynecological pain conditions such as CPP and endometriosis, there may be more pernicious obstacles. The deleterious impact of stigma is well described in the medicinal cannabis cohort, and whilst some have proposed that stigma is diminishing due to normali- zation in certain localities, there is little evidence to suggest it has disappeared [103]. Recent data from the UK of 2319 patients utilizing cannabis-based medicines (CBMs) indicated that participants were afraid of what the police or criminal justice system (57.1%), other government agencies (55.3%), and healthcare professionals (40.2%) might think about their treatment choice, suggestive of a high prevalence of perceived stigma [104]. Qualitative research of people utilizing illicit cannabis for therapeutic purposes shows that stigmatization is related to, and perpetuated by, the ambiguous status of can- nabis (i.e., both a legal medicine and illegal drug) and the lack of knowledge about medical cannabis amongst police, medical professionals, and the general public [105]. Additional qualita- tive research exploring the barriers, drivers and perceptions of cannabis use for primary dysmenorrhea (PD) in Australian women [106] goes further, showing that the perceived dam- age to their professional and social standing if their cannabis use became known was a serious concern, despite its legality for medical purposes. Participants spoke about the clandestine 1576 J. Sinclair et al. way they had to consume cannabis for their pain and symp- toms, and that even the possibility of being perceived as irre- sponsible, simply by virtue of being a cannabis user, was a significant barrier to adoption [106]. Stigma not only impacts people directly, but also indirectly in the bias and opinions of the healthcare professionals they interact with. Surveyed pharmacists have highlighted the impact that stigma can have on patients, with the lack of public awareness and inability to distinguish between medicinal and recreational cannabis identified as key factors contributing to public stigma [107, 108]. Furthermore, effective treatment with medicinal canna- bis may be compromised by negative attitudes, stigmatized perceptions, and subjective norms of nurses and physicians [109], highlighting that health education for both health pro- fessionals and the general public plays a crucial role in reduc- ing the impact of stigma [110]. This is particularly detrimental given that women with CPP and associated conditions such as endometriosis already experience stigma and discrimination [111, 112]. The impact of such stigma permeates into government laws and corporate policies, notably drug-driving laws and workplace drug testing policies [113, 114]. This is a significant challenge as cannabis is one or more of (a) a legal medicine, (b) a recreational/adult-use drug, and (c) an illicit/illegal substance, depending on geographic location and legal jurisdiction. This is reflected in the haze of issues with preexisting drug-driving laws and workplace policies. Whilst road safety risks associated with the medicinal use of cannabis appear to be similar or lower than other potentially impairing prescription medications [90], including those commonly used in endometriosis such as opioids, in coun- tries such as Australia, patients utilizing medicinal cannabis are still subject to drug-driving testing, which detects for presence of THC alone, not impairment. Such laws crimi- nalize the presence of THC in body fluids irrespective of impairment and appears to be linked to the historical status of cannabis as a Schedule 9 substance with no recognized medical value [90]. Research has shown, particularly in those living in regional and remote locations, that facing such criminal prosecution for driving whilst using canna- bis legally as a medicine is a significant barrier to adoption [106], giving rise to the need for updated drug-driving laws. Similarly, workers in high-risk industries such as defense, construction, railroad, transport, maritime, and mining oper- ations are similarly disadvantaged as these occupations are usually subjected to workplace drug testing policies [49]. 8 Illicit versus Legal Medicinal Cannabis Illicit cannabis is unlikely to have any accurate indication of the level of THC, and the lack of any quality control precludes consistency, making consistent dosing for medical purposes next to impossible. Medicinal cannabis undergoes rigorous testing procedures including microbial limits, cannabinoid standardization, detection of foreign matter, aflatoxins, ochra- toxin A, pesticide and solvent residues. This ability to culti- vate and standardize cannabinoids and manufacture medicinal cannabis products to high quality standards with reproducible

means that accurate dosing is now possible [115, 116]. Unfortunately, the very ability to manufacture to these high standards is now contributing to a significant cost-to-patient burden, which can in turn drive people to illicit or recreational markets to source cannabis for therapeutic self-management. International survey data from this team (manuscript under submission) examining the use of cannabis for endometriosis pain and associated symptoms has identified that in countries such as Canada and the US, that have both legal medical and recreational/adult-use models, most survey respondents were utilizing recreational/adult-use cannabis for therapeutic self- administration over that of medical doctor prescription. Policy makers in countries with newly minted medical cannabis pro- grams need to consider the impact to public health that initiat- ing adult-use legalization may have on the medical cannabis sector and consider thoughtful approaches to ensuring a co- habitation of both is possible. 9 Conclusion A variety of evidence shows that cannabis usage, either illicit or legally prescribed, is relatively common amongst those with chronic pelvic pain. Cannabis appears to reduce pain and other symptoms of endometriosis such as gastro- intestinal issues, with corresponding reported reductions or cessation in medications commonly used to manage these symptoms such as opioids. Cannabis inhabits an unusual position in our modern pharmacopoeia, being both a legal medicine, a legal recreational drug, and an illegal drug, depending on jurisdiction. This has led to issues with driv - ing, workplace laws, and stigmatization that limit its usage as a legal medication. Clinicians working with endometriosis patients should be aware of high levels of cannabis usage amongst this population and monitor any reductions in regu- lar medication, especially in the case of opioids and benzo- diazepines. While promising, the safety and effectiveness of cannabis for various gynecological pain conditions needs to be tested in rigorous clinical trials. Acknowledgments Funding has been provided to JS in the form of a Western Sydney University Post-Graduate Research Scholarship. Declarations Funding Open Access funding enabled and organized by CAUL and its Member InstitutionS. JS PhD is supported by a Western Sydney University Post-Graduate Research Scholarship; however, no specific funding was provided for preparing this manuscript. 1577 Cannabis for Gynecological Conditions Competing Interests As a medical research institute, NICM Health Research Institute (at Western Sydney University) receives research grants and donations from foundations, universities, government agen- cies, and industry. Sponsors and donors provide united and tied fund- ing for work to advance the vision and mission of the Institute. JS is employed by Australian Natural Therapeutics Group, and formerly sat on the scientific advisory board for BioCeuticals. JS is also a current member of the scientific advisory board for United in Compassion (pro bono) and a board member of the Australian Medicinal Canna- bis Association (pro bono). JA reports grant funding from MRFF for multiple endometriosis-related research grants; honoraria, member on Advisory Boards with Hologic Australia and CSL Vifor (formerly Vifor Pharma Pty. Ltd.); is a member of the Endometriosis Advisory Group to the Australian Government, Chairs the Expert Endometriosis Work- ing Group for the Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG), was the chair for the publication of the Diagnosis and Management of Endometriosis Clinical Guide - line in 2021; and is the Deputy Editor of the Journal of Minimally Invasive Gynecology and Associate Editor of the Australian and New Zealand Journal of Obstetrics and Gynaecology. MA is an advisory board member for Evolv Health, reports grant funding from MRFF for multiple endometriosis-related research grants, is chair of Endome- triosis Australia’s Clinical Advisory Committee, and is a member of the Expert Endometriosis Working Group for the Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG). AP declares that they have no conflicts of interest that might be relevant to the contents of this manuscript. Author Contributions JS and MA wrote the main manuscript. JA and AP provided feedback to the main manuscript. All authors reviewed the manuscript prior to submission. Ethics Approval Not applicable. Consent (Participation & Publication) Not applicable. Data Availability Data sharing not applicable to this article as no data- sets were generated or analyzed during the current study. Code Availability Not applicable. Open Access This article is licensed under a Creative Commons Attri- bution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Com- mons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regula- tion or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

1. Gynecological diseases - Level 3 cause. Institute for Health Met- rics and Evaluation. 2019; https:// www. healt hdata. org/ resul ts/ gbd_ summa ries/ 2019/ gynec ologi cal- disea ses- level-3- cause#: ~: text= Summa ry% 20Gyn aecol ogical% 20dis eases% 20cau sed% 20a,with% 20gyn aecol ogical% 20dis eases% 20in% 202019. Accessed 3 June 2023. 2. Armour M, et al. The prevalence and academic impact of dys- menorrhea in 21,573 young women: a systematic review and meta-analysis. J Womens Health (Larchmt). 2019;28(8):1161–71. 3. Coco AS. Primary dysmenorrhea. Am Fam Physician. 1999;60(2):489–96. 4. Proctor M, Farquhar C. Diagnosis and management of dysmenor- rhoea. BMJ. 2006;332(7550):1134–8. 5. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol. 2006;108(2):428–41. 6. Morrow C, Naumburg EH. Dysmenorrhea. Prim Care. 2009;36(1):19–32 (vii). 7. Zahradnik HP, Hanjalic-Beck A, Groth K. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review. Contraception. 2010;81(3):185–96. 8. Armour M, et al. The prevalence and educational impact of pel- vic and menstrual pain in Australia: a National Online Survey of 4202 Young Women Aged 13–25 Years. J Pediatr Adolesc Gynecol. 2020;33(5):511–8. 9. Parker MA, Sneddon AE, Arbon P. The menstrual disorder of teenagers (MDOT) study: determining typical menstrual pat- terns and menstrual disturbance in a large population-based study of Australian teenagers. BJOG. 2010;117(2):185–92. 10. Schoep ME, et al. Productivity loss due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748 women. BMJ Open. 2019;9(6): e026186. 11. Holmes K, et al. Adolescent Menstrual Health Literacy in Low, Middle and High-Income Countries: A Narrative Review. Int J Environ Res Public Health. 2021;18(5):2260. 12. Armour M, et al. Menstrual Health Literacy and Management Strategies in Young Women in Australia: a National Online Survey of Young Women Aged 13–25 Years. J Pediatr Adolesc Gynecol. 2021;34(2):135–43. 13. Sinclair J, et al. Should I inhale?;Perceptions, barriers, and drivers for medicinal cannabis use amongst australian women with primary dysmenorrhoea: a qualitative study. Int J Environ Res Public Health. 2022;19(3):1536. 14. Howard F, et al. Pelvic pain: diagnosis and management. Phila- delphia: Lippincott Williams and Wilkins; 2000. 15. Hawkey A, et al. “A day-to-day struggle”: A comparative quali- tative study on experiences of women with endometriosis and chronic pelvic pain. Femin Psychol. 2022;32:482–500. 16. Moradi M, et al. Impact of endometriosis on women’s lives: a qualitative study. BMC Womens Health. 2014;14(1):123. 17. Armour M, et al. Endometriosis and the workplace: lessons from Australia’s response to COVID-19. Aust N Z J Obstet Gynaecol. 2022;62(1):164–7. 18. Lamvu G, et al. Chronic pelvic pain in women: a review. JAMA. 2021;325(23):2381–91. 19. Armour M, et al. Endometriosis and chronic pelvic pain have similar impact on women, but time to diagnosis is decreasing: an Australian survey. Sci Rep. 2020;10(1):16253. 20. Ahangari A. Prevalence of chronic pelvic pain among women: an updated review. Pain Physician. 2014;17(2):E141–7. 21. Liang AL, Gingher EL, Coleman JS. Medical cannabis for gynecologic pain conditions: a systematic review. Obstet Gynecol. 2022;139(2):287–96. 22. Armour M, et al. The cost of illness and economic burden of endometriosis and chronic pelvic pain in Australia: A national online survey. PLoS ONE. 2019;14(10): e0223316. 23. Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ. 2014;348: g1752. 24. Armour M, et al. Self-care strategies and sources of knowl- edge on menstruation in 12,526 young women with dysmen- orrhea: A systematic review and meta-analysis. PLoS ONE. 2019;14(7): e0220103. 1578 J. Sinclair et al. 25. Evans S, et al. Treatment use and satisfaction in Australian women with endometriosis: a mixed-methods study. Intern Med J. 2022;52(12):2096–106. 26. Sinaii N, et al. Treatment utilization for endometriosis symp- toms: a cross-sectional survey study of lifetime experience. Fertil Steril. 2007;87(6):1277–86. 27. As-Sanie S, et al. Healthcare utilization and cost burden among women with endometriosis by opioid prescription status in the first year after diagnosis: a retrospective claims database analy - sis. J Med Econ. 2020;23:1–7. 28. Chiuve SE, et al. Chronic opioid use and complication risks in women with endometriosis: a cohort study in US administra- tive claims. Pharmacoepidemiol Drug Saf. 2021;30:787–96. 29. Armour M, et al. Lessons from implementing the Australian National Action Plan for Endometriosis. Reproduction and Fer - tility, 2022: p. RAF-22-0003. 30. Roman H, et al. Long-term risk of repeated surgeries in women managed for endometriosis: a 1,092 patient-series. Fertil Steril. 2023;120:870–9. 31. Horne AW, et al. Top ten endometriosis research priorities in the UK and Ireland. Lancet. 2017;389(10085):2191–2. 32. Rogers PA, et al. Research priorities for endometriosis. Reprod Sci. 2017;24(2):202–26. 33. Armour M, et al. Endometriosis research priorities in Australia. Aust N Z J Obstet Gynaecol. 2023;63:594–8. 34. Russo EB. History of cannabis and its preparations in saga, sci- ence, and sobriquet. Chem Biodivers. 2007;4(8):1614–48. 35. Clarke R, Merlin MD. Cannabis evolution and ethnobotany. Berkeley: University of California Press; 2013. 36. Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr. 2006;28(2):153–7. 37. Russo EB. Cannabis treatments in obstetrics and gynecology: a historical review. J Cannabis Therap. 2002;2(3–4):5–35. 38. Touwn M. The religious and medicinal uses of Cannabis in China, india and Tibet. J Psychoactive Drugs. 1981;13:23–34. 39. Churchill F. Essays on the puerperal fever and other diseases peculiar to women. London: Sydenham Society; 1849. 40. Christison A. On the natural history, action, and uses of Indian Hemp. Mon J Med Sci. 1851;4(19):26–45. 41. Willis I. Cannabis indica. Boston Med Surg J. 1859;61:173–8. 42. Brown J. Cannabis indica; A valuable remedy in menorrhagia. BMJ. 1883;1:1002. 43. Hare H. Clinical and physiological notes on the action of Can- nabis indica. Therapeutic Gazette. 1887;2:225–8. 44. Clendinning J. Observation on the medicinal properties of Canna- bis sativa from India. Medico-Chirurg Trans. 1843;26:188–210. 45. Russo E. The pharmacological history of cannabis. In: Pertwee R, editor. Handbook of Cannabis. Oxford: Oxford University Press; 2016. p. 23–43. 46. Pereira P. The elements of materia medica and therapeutics. Philadelphia: Lea & Blanchard; 1843. 47. Fankhauser M. History of cannabis in Western Medicine. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. New York: Hawthorn Integrative Healing Press; 2002. p. 1–439. 48. Bridgeman MB, Abazia DT. Medicinal Cannabis: History, Phar- macology, And Implications for the Acute Care Setting. P T. 2017;42(3):180–8. 49. Sinclair J, Adams C, Thurgood G-R, Davidson M, Armour M, Sarris J. Cannabidiol (CBD) oil: Rehashing the research, roles and regula- tions in Australia. Austra J Herb Naturopathic Med. 2020;32:54–60. 50. Duke S. Cannabis captiva: freeing the world from marijuana pro- hibition. Georgetown J Int Affairs. 2010;11:83–90. 51. Gaoni Y, Mechoulam R. Isolation, structure and partial syn- thesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646–7. 52. Crocq MA. History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci. 2020;22(3):223–8. 53. Castillo A, et al. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol Dis. 2010;37(2):434–40. 54. Jones NA, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther. 2010;332(2):569–77. 55. Bergamaschi MM, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36(6):1219–26. 56. Zanelati TV, et al. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Phar - macol. 2010;159(1):122–8. 57. Mukhopadhyay P, et al. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory sign- aling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med. 2011;50(10):1368–81. 58. Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (Basel). 2019;9(1):21. 59. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neuro- therapeutics. 2009;6(4):713–37. 60. Haney M, et al. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychop- harmacology. 2005;181(1):170–8. 61. Kavia RB, et al. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler. 2010;16(11):1349–59. 62. Russo EB. Taming THC: potential cannabis synergy and phy - tocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344–64. 63. Hanus LO, et al. Phytocannabinoids: a unified critical inven- tory. Nat Prod Rep. 2016;33(12):1357–92. 64. Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease–successes and failures. FEBS J. 2013;280(9):1918–43. 65. McPartland JM, Guy GW, Di Marzo V. Care and feeding of the endocannabinoid system: a systematic review of potential clini- cal interventions that upregulate the endocannabinoid system. PLoS ONE. 2014;9(3): e89566. 66. Henry RJ, et al. For whom the endocannabinoid tolls: Modula- tion of innate immune function and implications for psychi- atric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:167–80. 67. Walker OS, Holloway AC, Raha S. The role of the endocan- nabinoid system in female reproductive tissues. J Ovarian Res. 2019;12(1):3. 68. Gentilini D, et al. Endocannabinoid system regulates migra- tion of endometrial stromal cells via cannabinoid receptor 1 through the activation of PI3K and ERK1/2 pathways. Fertil Steril. 2010;93(8):2588–93. 69. Di Blasio AM, Vignali M, Gentilini D. The endocannabinoid pathway and the female reproductive organs. J Mol Endocrinol. 2013;50(1):R1-9. 70. Sanchez AM, et al. Elevated systemic levels of endocan- nabinoids and related mediators across the menstrual cycle in women with endometriosis. Reprod Sci. 2016;23(8):1071–9. 71. Dmitrieva N, et al. Endocannabinoid involvement in endome- triosis. Pain. 2010;151(3):703–10. 72. Sanchez AM, et al. The molecular connections between the cannabinoid system and endometriosis. Mol Hum Reprod. 2012;18(12):563–71. 1579 Cannabis for Gynecological Conditions 73. Bouaziz J, et al. The clinical significance of endocannabinoids in endometriosis pain management. Cannabis Cannabinoid Res. 2017;2(1):72–80. 74. Maia J, et al. The fundamental role of the endocannabinoid system in endometrium and placenta: implications in patho - physiological aspects of uterine and pregnancy disorders. Hum Reprod Update. 2020;26(4):586–602. 75. Shen X, et al. Expression of cannabinoid receptors in myome- trium and its correlation with dysmenorrhea in adenomyosis. Reprod Sci. 2019;26(12):1618–25. 76. Piomelli D, Sasso O. Peripheral gating of pain signals by endogenous lipid mediators. Nat Neurosci. 2014;17(2):164–74. 77. Rice AS. Cannabinoids and pain. Curr Opin Investig Drugs. 2001;2(3):399–414. 78. Hill KP, et al. Cannabis and pain: a clinical review. Cannabis Cannabinoid Res. 2017;2(1):96–104. 79. Ahluwalia J, et  al. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience. 2000;100(4):685–8. 80. Milligan AL, Szabo-Pardi TA, Burton MD. Cannabinoid receptor type 1 and its role as an analgesic: an opioid alternative? J Dual Diagn. 2020;16(1):106–19. 81. Marcu I, Gee A, Lynn B. Cannabinoids and chronic pelvic pain in women: focus on endometriosis. J Endomet aPelvic Pain Disord. 2021;13(3):155–65. 82. Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug Targets. 2009;8(6):403–21. 83. Ibrahim MM, et al. CB2 cannabinoid receptor activation pro- duces antinociception by stimulating peripheral release of endog- enous opioids. Proc Natl Acad Sci U S A. 2005;102(8):3093–8. 84. Manzanares J, Julian M, Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the man- agement of acute and chronic pain episodes. Curr Neuropharma- col. 2006;4(3):239–57. 85. Ibrahim MM, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A. 2003;100(18):10529–33. 86. Muller C, Morales P, Reggio PH. Cannabinoid ligands targeting TRP channels. Front Mol Neurosci. 2018;11:487. 87. Pisanti S, et al. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. J Cell Physiol. 2007;211(2):495–503. 88. Leconte M, et  al. Antiproliferative effects of cannabinoid agonists on deep infiltrating endometriosis. Am J Pathol. 2010;177(6):2963–70. 89. Clarke H, Fitzcharles M. The evolving culture of medical can- nabis in Canada for the management of chronic pain. Front Phar- macol. 2023;14:1153584. 90. Perkins D, et al. Medicinal cannabis and driving: the intersec- tion of health and road safety policy. Int J Drug Policy. 2021;97: 103307. 91. Armour M, Sinclair J. Cannabis for endometriosis-related pain and symptoms: It’s high time that we see this as a legitimate treatment. Aust N Z J Obstet Gynaecol. 2023;63(1):118–20. 92. Carrubba AR, et  al. Use of cannabis for self-manage- ment of chronic pelvic pain. J Womens Health (Larchmt). 2021;30(9):1344–51. 93. Armour M, et al. Self-management strategies amongst Austral- ian women with endometriosis: a national online survey. BMC Complement Altern Med. 2019;19(1):17. 94. Sinclair J, Smith CA, Abbott J, Chalmers KJ, Pate DW, Armour M. Cannabis use, a self-management strategy among australian women with endometriosis: results from a National Online Sur- vey. J Obstet Gynaecol Can. 2020;42:256–61. https:// doi. org/ 10. 1016/j. jogc. 2019. 08. 033. 95. Sinclair J, et al. Effects of cannabis ingestion on endometrio- sis-associated pelvic pain and related symptoms. PLoS ONE. 2021;16(10): e0258940. 96. MacCallum CA, Russo EB. Practical considerations in medi- cal cannabis administration and dosing. Eur J Intern Med. 2018;49:12–9. 97. Armour M, et al. Endometriosis and cannabis consumption dur- ing the COVID-19 pandemic: an international cross-sectional survey. Cannabis Cannabinoid Res. 2022;7(4):473–81. 98. Armour M, et al. Illicit cannabis usage as a management strategy in New Zealand women with endometriosis: an online survey. J Womens Health (Larchmt). 2021;30(10):1485–92. 99. Sinclair J, et al. Cannabis use for endometriosis: clinical and legal challenges in Australia and New Zealand. Cannabis Cannabinoid Res. 2022;7(4):464–72. 100. MacCallum CA, Lo LA, Boivin M. “Is medical cannabis safe for my patients?” A practical review of cannabis safety considera - tions. Eur J Intern Med. 2021;89:10–8. 101. Petursson H. The benzodiazepine withdrawal syndrome. Addic- tion. 1994;89(11):1455–9. 102. Pergolizzi JV Jr, Raffa RB, Rosenblatt MH. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. J Clin Pharm Ther. 2020;45(5):892–903. 103. Reid M. A qualitative review of cannabis stigmas at the twilight of prohibition. J Cannabis Res. 2020;2(1):46. 104. Troup LJ, et al. Perceived stigma of patients undergoing treat- ment with cannabis-based medicinal products. Int J Environ Res Public Health. 2022;19(12):7499. 105. Bottorff JL, et al. Perceptions of cannabis as a stigmatized medi- cine: a qualitative descriptive study. Harm Reduct J. 2013;10:2. 106. Sinclair J, et al. “Should I Inhale?”-perceptions, barriers, and drivers for medicinal cannabis use amongst Australian women with primary dysmenorrhoea: a qualitative study. Int J Environ Res Public Health. 2022;19(3):1536. 107. Isaac S, Saini B, Chaar BB. The Role of Medicinal Cannabis in Clinical Therapy: Pharmacists’ Perspectives. PLoS ONE. 2016;11(5): e0155113. 108. Sabmeethavorn Q, Bonomo YA, Hallinan CM. Pharmacists’ perceptions and experiences of medicinal cannabis dispensing: a narrative review with a systematic approach. Int J Pharm Pract. 2022;30(3):204–14. 109. Melnikov S, et al. The effect of attitudes, subjective norms and stigma on health-care providers’ intention to recommend medici- nal cannabis to patients. Int J Nurs Pract. 2021;27(1): e12836. 110. Clobes T, Palmier LA, Gagnon M, Klaiman C, Arellano M. The impact of education on attitudes toward medical cannabis. PEC Innovation. 2022;1:1–5. 111. Young K, Fisher J, Kirkman M. Women’s experiences of endo- metriosis: a systematic review and synthesis of qualitative research. J Fam Plann Reprod Health Care. 2015;41(3):225–34. 112. Young K, Fisher J, Kirkman M. Clinicians’ perceptions of wom- en’s experiences of endometriosis and of psychosocial care for endometriosis. Aust N Z J Obstet Gynaecol. 2017;57(1):87–92. 113. Howard J, Osborne J. Cannabis and work: need for more research. Am J Ind Med. 2020;63(11):963–72. 114. McCartney D, et al. Determining the magnitude and duration of acute Delta(9)-tetrahydrocannabinol (Delta(9)-THC)-induced driving and cognitive impairment: a systematic and meta-analytic review. Neurosci Biobehav Rev. 2021;126:175–93. 115. Therapeutic Goods Order No. 93 (Standard for Medicinal Can- nabis). Australian Federal Government. Department of Health: Canberra, ACT Australia; 2017. 116. Upton R, ElSohly M, Romm A, Russo E, Sexton M, editors. Cannabis inflorescence. Scotts Valley: American Herbal Phar - macopoeia; 2013. p. 55.